Avalo Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Avalo Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Avalo Therapeutics Inc
Rating: 1.83366675
Author: Trendlyne DVM scores

about

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also incl...

9.26 -0.08 (-0.86%)

42.12% Fall from 52W High

9,083

XNAS Volume

XNAS 29 Aug, 2025 10:00 AM (EDT)

Not Eligible

Expensive Valuation

14.7 / 100

Technically Neutral

58.7 / 100

1Yr Price target upside is 233%

7 analysts

Avalo Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Avalo Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also incl...

42.12% Fall from 52W High

SWOT Analysis

Avalo Therapeutics Inc Live Price Chart